Compare Janus Living Inc. Class A-1 Common Stock (JAN) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Janus Living Inc. Class A-1 Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $28.51 (market cap $6.76B), while Relay Therapeutics Inc. Common Stock trades at $17.23 (market cap $3.81B). The key difference: Janus Living Inc. Class A-1 Common Stock is the larger of the two by market cap, and Janus Living Inc. Class A-1 Common Stock pays a 1.98% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.
| JAN | RLAY | |
|---|---|---|
Market Cap | $6.76B | $3.81B |
Volume | 1,332,082 | 1,706,150 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $20.75 |
52-Week Low | $22.88 | $6.05 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $6.85B | $2.93B |
Dividend Yield | 1.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
